Display search results for ** instead (38 products)

Showing 11-20 of 38

This issue of Vital Signs, released on January 17, 2014, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for our core markets including Pharma/Biotech, In Vitro Diagnostics, Advanced Medical Technology, and Connected Health.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on September 30, 2013, provides a market overview and drug pipeline analysis of Type 2 diabetes therapeutics. Additionally, a company spotlight is provided for Trovagene in San Diego, CA. The company has a proprietary transrenal nucleic acid platform with the potential to deliver superior molecular diagnostics i...

USD 450.00

USD 337.50 save 25 %

Given the importance of the changes from PPACA and the creation of the health insurance marketplaces, we are providing our online Frost.com blog on HIX in collected form for the month of September for ease of use by our subscription clients. This discussion is brought to you by our Connected Health research program. Please also follow our blog, par...

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on February 28, 2014, discusses three M&A transactions this month by Nestle, Myriad Genetics, and Fludigm and what these deals mean for the industry. Additionally, Illuminas first stab at personalized medicine through a partnership with Amgen is explored.

USD 450.00

USD 337.50 save 25 %

Given the importance of the changes from PPACA and the creation of the health insurance marketplaces, we are providing our online Frost.com blog on HIX in collected form for the month of August for ease of use by our subscription clients. This discussion is brought to you by our Connected Health research program. Please also follow our blog, part o...

USD 450.00

USD 337.50 save 25 %

Given the importance of the changes from PPACA and the creation of the health insurance marketplaces, we are providing our online Frost.com blog on HIX in collected form for the month of September for ease of use by our subscription clients. This discussion is brought to you by our Connected Health research program. Please also follow our blog, par...

USD 450.00

USD 337.50 save 25 %

The wearables market is currently a center of hype and interest across the varied landscape of consumers, vendors, providers, payers, and other stakeholders interested in the broader digital health market. Companies are trying to better understand consumer habits, exploring device monetization outside of the early adopting fitness crowd, increasing...

USD 450.00

USD 337.50 save 25 %

Electronic cigarettes and vaping products have taken the tobacco industry by storm. Multiple public reports have e-cigarettes surpassing traditional tobacco sales within the next six to ten years if growth rates continue to climb. Due to the lack of Food and Drug Administration (FDA) regulation, e-cigarette year-over-year growth declined from 2010-...

USD 450.00

USD 337.50 save 25 %

21 Sep 2015  |  North America

Vital Signs - Review of AHRA 2015: Key Conference Takeaways and Gadolinium Based MR Contrast Agents Safety Issues

Overview of Top Themes from the 2015 Annual Meeting of the Association for Medical Imaging Management (AHRA)

A record-high attendance of 1,000 radiology directors and managers convened to the 2015 Annual Meeting of the Association for Medical Imaging Management (AHRA 2015) held this year in Las Vegas. Radiology is going through interesting times indeed. Under the coordinated care paradigm that is gradually emerging in the U.S., and with all the changes th...

USD 450.00

USD 337.50 save 25 %

18 Mar 2016  |  North America

Vital Signs - Drug Development Focus on Genetically Modified Swine

Modified Swine Hold out Promise of Improving Pre-Clinical Efficacy, Lowering Multi-billion Dollar Drug and Device Development Costs

The US pharmaceutical industry spends approximately $100 billion annually to develop new pharmaceutical drugs and medical devices. Today, a new drug takes approximately 15 years and over $1 billion to bring to market. Product development costs could be greatly reduced by using animal models that more closely resemble humans in their disease states ...

USD 450.00

USD 337.50 save 25 %

Showing 11-20 of 38